Lercan (Lercanidipine Hydrochloride)

Lercanidipine is employed in the management of hypertension, a chronic condition where persistently high arterial pressure increases the risk of heart attack, stroke, and kidney disease. By targeting vascular smooth muscle, the medication helps achieve blood pressure control.

• Hypertension: reduces both systolic and diastolic blood pressure, lowering risk of cardiovascular events.
• Isolated systolic hypertension: preferentially lowers systolic pressure, beneficial in older adults.

• Lercanidipine selectively blocks L-type calcium channels in vascular smooth muscle cells. Inhibition of calcium influx prevents contraction, causing dose‑dependent vasodilation of arterioles. The resulting decrease in peripheral vascular resistance leads to lowered arterial pressure without significant effect on heart rate or cardiac contractility. Its high lipophilicity allows prolonged action and smooth onset, contributing to once‑daily dosing. The drug is extensively metabolized by the liver, primarily via CYP3A4, and its metabolites are excreted in the urine and feces.

Lercanidipine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Headache: mild to moderate pain often occurring after dose initiation.
• Flushing: transient warmth and redness of the skin.
• Peripheral edema: swelling of the ankles or lower legs.
• Dizziness: light‑headed sensation, especially when standing quickly.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure that may cause fainting.
• Myocardial infarction: rare occurrence of heart attack.
• Hepatic dysfunction: abnormal liver enzymes or hepatitis.
• Anaphylactic reaction: life‑threatening allergy with rash, swelling, and breathing difficulty.

When prescribing Lercanidipine, clinicians should consider several safety measures.

• Dose adjustment: required in patients with hepatic impairment.
• Monitor blood pressure: check regularly after initiation or dose changes.
• Avoid abrupt discontinuation: may cause rebound hypertension.
• Caution in elderly: increased sensitivity to hypotensive effects.
• Drug interactions: review concomitant medications that affect CYP3A4.
• Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Lercanidipine can interact with several medicines, necessitating careful review.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels, risk of hypotension.
• Grapefruit juice: can elevate drug concentration, leading to excessive vasodilation.
• Simultaneous use with other calcium channel blockers: additive blood pressure lowering effect.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.
• Diuretics: may enhance hypotensive response.
• Beta‑blockers: combined effect on heart rate and blood pressure may require dose adjustment.